NCT07073781 Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation
| NCT ID | NCT07073781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leeds Beckett University |
| Condition | Impaired Glucose Regulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-08-15 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-08-15 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.
Eligibility Criteria
Inclusion Criteria * Aged 18-40 years * Body Mass Index (BMI) between 25.0 and 29.9 kg/m² (classified as overweight) * In good general health (self-reported) * Normal self-reported sleep patterns, with no history of diagnosed sleep disorders * Willing and able to provide informed consent * Able to comply with study procedures, including fasting and oral glucose tolerance testing Exclusion Criteria: * Diagnosed diabetes (any type). * Diagnosed sleep disorders. * Fasting glucose \>6.9 mmol/L during screening. * History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy). * Major surgery, significant illness, trauma, infection, or myocardial infarction within the past 6 weeks. * Current use of medications affecting glucose metabolism or probiotics * Pregnancy or actively trying to conceive * Night shift work within the past month
Contact & Investigator
Lewis F Hepburn, Msc
PRINCIPAL INVESTIGATOR
Leeds Beckett University
Frequently Asked Questions
Who can join the NCT07073781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Impaired Glucose Regulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07073781 currently recruiting?
Yes, NCT07073781 is actively recruiting participants. Contact the research team at l.hepburn3449@student.leedsbeckett.ac.uk for enrollment information.
Where is the NCT07073781 trial being conducted?
This trial is being conducted at Leeds, United Kingdom.
Who is sponsoring the NCT07073781 clinical trial?
NCT07073781 is sponsored by Leeds Beckett University. The principal investigator is Lewis F Hepburn, Msc at Leeds Beckett University. The trial plans to enroll 70 participants.